Investigating the role of long non-coding RNA in hypertrophic cardiomyopathy

Graham A Branscom1, Michael Morley1, Jonathan J Herrera2

  • 1Cardiology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Insights

Researchers identified long non-coding RNAs (lncRNAs) involved in hypertrophic cardiomyopathy (HCM). They found specific lncRNAs with potential to code for micropeptides, offering new targets for HCM research.

Area of Science:

  • Genomics
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Long non-coding RNAs (lncRNAs) are crucial regulators of gene expression.
  • Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease with incompletely understood molecular mechanisms.

Purpose of the Study:

  • To identify novel long non-coding RNAs (lncRNAs) implicated in the pathophysiology of hypertrophic cardiomyopathy (HCM).
  • To explore the potential for these lncRNAs to encode functional micropeptides.

Main Methods:

  • Analysis of RNA-Seq data from a mouse model of HCM and human HCM tissue.
  • Cross-referencing mouse transcripts with human orthologs.
  • Utilizing computational tools (MiPepid, AlphaFold, PhyloCSF) to predict micropeptide coding potential.

Main Results:

  • Identified 35 differentially expressed lncRNAs in the mouse HCM model.
  • Found 13 lncRNAs with human orthologs.
  • Predicted micropeptides from three lncRNAs (G730003C15Rik, 9830004L10Rik, Gm45012) showed high folding confidence.
  • Two lncRNAs (6330403L08Rik, 2900072N19Rik) exhibited positive PhyloCSF scores, indicating micropeptide potential.

Conclusions:

  • Developed a computational workflow for identifying disease-associated lncRNAs.
  • Highlighted specific lncRNAs with cross-species conservation and micropeptide coding potential as promising candidates for further investigation in HCM.
  • Suggests a novel role for lncRNA-derived micropeptides in HCM pathogenesis.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
56
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41